Efficacy of cannabinoids in fibromyalgia: a literature review

Keywords: Fibromyalgia, Medical marijuana, Cannabinoids, Dronabinol, Tetrahydrocannabinol, Cannabidiol

Abstract

Fibromyalgia is a chronic disease of unclear etiology, involving a neural oversensitization and impaired pain modulation, in addition to a clinical deficiency of the endocannabinoid system. Fibromyalgia is associated with a number of somatic and psychological disorders and hence multiple pharmacological approaches have been used, including   opioids, antidepressants, antiepileptics, and more recently medical cannabis. This narrative review comprises a review of the current literature on the efficacy of   cannabinoids in fibromyalgia. The studies describe a possible influence of cannabis on pain control in patients with fibromyalgia, with positive effects on quality of life and sleep. The use of cannabis seems to be beneficial in patients with fibromyalgia; however, more robust studies are still needed to establish is actual efficacy in pain management, quality of life and improvement of associated symptoms.

References

Doebl S, Macfarlane GJ, Hollick RJ. "No one wants to look after the fibro patient". Understanding models, and patient perspectives, of care for fibromyalgia: reviews of current evidence. Pain. 2020;161(8):1716-25. DOI: http://www.doi.org/10.1097/j.pain.0000000000001870

Neumeister MW, Neumeister EL. Fibromyalgia. Clin Plast Surg. 2020;47(2):203-13. doi: https://doi.org/10.1016/j.cps.2019.12.007

García del Pozo J, Álvarez Martínez M. Prevención y dietoterapia de la obesidad. Offarm Farm y Soc. 2002;21(7):102-6.

Sumpton JE, Moulin DE. Fibromyalgia. Handb Clin Neurol. 2014;119:513-27. doi: https://doi.org/10.1016/B978-0-7020-4086-3.00033-3

Tzadok R, Ablin JN. Current and emerging pharmacotherapy for fibromyalgia. Pain Res Manag. 2020: 6541798. doi: https://doi.org/10.1155/2020/6541798

Queiroz LP. Worldwide epidemiology of fibromyalgia. Curr Pain Headache Rep. 2013;17(8):356. doi: https://doi.org/10.1007/s11916-013-0356-5

Clauw DJ. Fibromyalgia: a clinical review. JAMA. 2014;311(15):1547-55. doi: https://doi.org/10.1001/jama.2014.3266

Calandre EP, Rico-Villademoros F, Slim M. An update on pharmacotherapy for the treatment of fibromyalgia. Expert Opin Pharmacother. 2015;16(9):1347-68. doi: https://doi.org/10.1517/14656566.2015.1047343

Lawson K. Potential drug therapies for the treatment of fibromyalgia. Expert Opin Investig Drugs. 2016;25(9):1071-81. doi: https://doi.org/10.1080/13543784.2016.1197906

Ablin JN, Häuser W. Fibromyalgia syndrome: novel therapeutic targets. Pain Manag. 2016;6(4):371-81. doi: https://doi.org/10.2217/pmt-2016-0007

Chinn S, Caldwell W, Gritsenko K. Fibromyalgia pathogenesis and treatment options update. Curr Pain Headache Rep. 2016;20(4):25. doi: https://doi.org/10.1007/s11916-016-0556-x

Blumenthal DE, Malemud CJ. Recent strategies for drug development in fibromyalgia syndrome. Expert Rev Neurother. 2016;16(12):1407-11. doi: https://doi.org/10.1080/14737175.2016.1207531

Gur A, Oktayoglu P. Advances in diagnostic and treatment options in patients with fibromyalgia syndrome. Open access Rheumatol Res Rev. 2009;1:193-209. doi: https://doi.org/10.2147/OARRR.S8040

Sarzi-Puttini P, Ablin J, Trabelsi A, Fitzcharles M-A, Marotto D, Häuser W. Cannabinoids in the treatment of rheumatic diseases: Pros and cons. Autoimmun Rev. 2019;18(12):102409. doi: https://doi.org/10.1016/j.autrev.2019.102409

Ko GD, Bober SL, Mindra S, Moreau JM. Medical cannabis - The Canadian perspective. J Pain Res. 2016;9:735-44. doi: https://doi.org/10.2147/JPR.S98182

Troutt WD, DiDonato MD. Medical Cannabis in Arizona: Patient characteristics, perceptions, and impressions of medical cannabis legalization. J Psychoactive Drugs. 2015;47(4):259-66. doi: https://doi.org/10.1080/02791072.2015.1074766

Gonen T, Amital H. Cannabis and cannabinoids in the treatment of rheumatic diseases. Rambam Maimonides Med J. 2020;11(1):e0007. doi: https://doi.org/10.5041/RMMJ.10389

García Rodríguez DF, Abud Mendoza C. Physiopathology of fibromyalgia. Reumatol Clin. 2020;16(3):191-4. doi: https://doi.org/10.1016/j.reumae.2020.02.004

Smith SC, Wagner MS. Clinical endocannabinoid deficiency (CECD) revisited: can this concept explain the therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions? Neuro Endocrinol Lett. 2014;35(3):198-201.

Russo EB. Clinical endocannabinoid deficiency reconsidered: Current research supports the theory in migraine, fibromyalgia, irritable bowel, and other treatment-resistant syndromes. Cannabis Cannabinoid Res. 2016;1(1):154-65. doi: https://doi.org/10.1089/can.2016.0009

Donvito G, Nass SR, Wilkerson JL, Curry ZA, Schurman LD, Kinsey SG, et al. The endogenous cannabinoid system: A budding source of targets for treating inflammatory and neuropathic pain. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 2018;43(1):52-79. doi: https://doi.org/10.1038/npp.2017.204

Farré M, Farré A, Fiz J, Torrens M. Cannabis use in fibromyalgia. Handbook of cannabis and related pathologies: biology, pharmacology, diagnosis, and treatment. Elsevier Inc.; 2017. p. 158-67. doi: https://doi.org/10.1016/B978-0-12-800756-3.00112-5

Di Marzo V, Piscitelli F. The endocannabinoid system and its modulation by phytocannabinoids. Neurother J Am Soc Exp Neurother. 2015;12(4):692-8. doi: https://doi.org/10.1007/s13311-015-0374-6

Burstein SH, Zurier RB. Cannabinoids, endocannabinoids, and related analogs in inflammation. AAPS J. 2009;11(1):109-19. doi: https://doi.org/10.1208/s12248-009-9084-5

Katz-Talmor D, Katz I, Porat-Katz B-S, Shoenfeld Y. Cannabinoids for the treatment of rheumatic diseases - where do we stand? Nat Rev Rheumatol. 2018;14(8):488-98. doi: https://doi.org/10.1038/s41584-018-0025-5

Katz D, Katz I, Porat-Katz BS, Shoenfeld Y. Medical cannabis: Another piece in the mosaic of autoimmunity? Clin Pharmacol Ther. 2017;101(2):230-8. doi: https://doi.org/10.1002/cpt.568

Schley M, Legler A, Skopp G, Schmelz M, Konrad C, Rukwied R. Delta-9-THC based monotherapy in fibromyalgia patients on experimentally induced pain, axon reflex flare, and pain relief. Curr Med Res Opin. 2006;22(7):1269-76. doi: https://doi.org/10.1185/030079906X112651

Skrabek RQ, Galimova L, Ethans K, Perry D. Nabilone for the treatment of pain in fibromyalgia. J Pain. 2008;9(2):164-73. doi: https://doi.org/10.1016/j.jpain.2007.09.002

Staud R, Koo EB. Are cannabinoids a new treatment option for pain in patients with fibromyalgia? Nat Clin Pract Rheumatol. 2008;4(7):348-9. doi: https://doi.org/10.1038/ncprheum0826

Ware MA, Fitzcharles M-A, Joseph L, Shir Y. The effects of nabilone on sleep in fibromyalgia: results of a randomized controlled trial. Anesth Analg. 2010;110(2):604-10. doi: https://doi.org/10.1213/ANE.0b013e3181c76f70

Sagy I, Bar-Lev Schleider L, Abu-Shakra M, Novack V. Safety and efficacy of medical cannabis in fibromyalgia. J Clin Med. 2019;8(6). doi: https://doi.org/10.3390/jcm8060807

Habib G, Avisar I. The consumption of cannabis by fibromyalgia patients in Israel. Pain Res Treat. 2018;2018:7829427. doi: https://doi.org/10.1155/2018/7829427

Yassin M, Oron A, Robinson D. Effect of adding medical cannabis to analgesic treatment in patients with low back pain related to fibromyalgia: an observational cross-over single centre study. Clin Exp Rheumatol. 2019;37(Suppl 1):13-20.

Giorgi V, Bongiovanni S, Atzeni F, Marotto D, Salaffi F, Sarzi-Puttini P. Adding medical cannabis to standard analgesic treatment for fibromyalgia: a prospective observational study. Clin Exp Rheumatol. 2020;38(Suppl 1):53-9.

Tsang CC, Giudice MG. Nabilone for the management of pain. Pharmacotherapy. 2016;36(3):273-86. doi: https://doi.org/10.1002/phar.1709

Stockings E, Campbell G, Hall WD, Nielsen S, Zagic D, Rahman R, et al. Cannabis and cannabinoids for the treatment of people with chronic noncancer pain conditions: a systematic review and meta-analysis of controlled and observational studies. Pain. 2018;159(10):1932-54. doi: https://doi.org/10.1097/j.pain.0000000000001293

Walitt B, Klose P, Fitzcharles M-A, Phillips T, Häuser W. Cannabinoids for fibromyalgia. Cochrane database Syst Rev. 2016;7(7):CD011694. doi: https://doi.org/10.1002/14651858.CD011694.pub2

Lynch ME, Campbell F. Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials. Br J Clin Pharmacol. 2011;72(5):735-44. doi: https://doi.org/10.1111/j.1365-2125.2011.03970.x

Fitzcharles M-A, Baerwald C, Ablin J, Häuser W. Efficacy, tolerability and safety of cannabinoids in chronic pain associated with rheumatic diseases (fibromyalgia syndrome, back pain, osteoarthritis, rheumatoid arthritis): A systematic review of randomized controlled trials. Schmerz. 2016;30(1):47-61. doi: https://doi.org/10.1007/s00482-015-0084-3

Häuser W, Petzke F, Fitzcharles MA. Efficacy, tolerability and safety of cannabis-based medicines for chronic pain management - An overview of systematic reviews. Eur J Pain. 2018;22(3):455-70. doi: https://doi.org/10.1002/ejp.1118

Sarzi-Puttini P, Batticciotto A, Atzeni F, Bazzichi L, Di Franco M, Salaffi F, et al. Medical cannabis and cannabinoids in rheumatology: where are we now? Expert Rev Clin Immunol. 2019;15(10):1019-32. doi: https://doi.org/10.1080/1744666X.2019.1665997

Ste-Marie PA, Fitzcharles M-A, Gamsa A, Ware MA, Shir Y. Association of herbal cannabis use with negative psychosocial parameters in patients with fibromyalgia. Arthritis Care Res (Hoboken). 2012;64(8):1202-8. doi: https://doi.org/10.1002/acr.21732

Alkabbani W, Marrie RA, Bugden S, Alessi-Severini S, Bolton JM, Daeninck P, et al. Persistence of use of prescribed cannabinoid medicines in Manitoba, Canada: a population-based cohort study. Addiction. 2019;114(10):1791-9. doi: https://doi.org/10.1111/add.14719

Vivian JA, Kishioka S, Butelman ER, Broadbear J, Lee KO, Woods JH. Analgesic, respiratory and heart rate effects of cannabinoid and opioid agonists in rhesus monkeys: antagonist effects of SR 141716A. J Pharmacol Exp Ther. 1998;286(2):697-703.

Fox A, Kesingland A, Gentry C, McNair K, Patel S, Urban L, et al. The role of central and peripheral Cannabinoid1 receptors in the antihyperalgesic activity of cannabinoids in a model of neuropathic pain. Pain. 2001;92(1-2):91-100. doi: https://doi.org/10.1016/S0304-3959(00)00474-7

Manning BH, Merin NM, Meng ID, Amaral DG. Reduction in opioid- and cannabinoid-induced antinociception in rhesus monkeys after bilateral lesions of the amygdaloid complex. J Neurosci. 2001;21(20):8238-46. doi: https://doi.org/10.1523/JNEUROSCI.21-20-08238.2001

Hsieh GC, Pai M, Chandran P, Hooker BA, Zhu CZ, Salyers AK, et al. Central and peripheral sites of action for CB₂ receptor mediated analgesic activity in chronic inflammatory and neuropathic pain models in rats. Br J Pharmacol. 2011;162(2):428-40. doi: https://doi.org/10.1111/j.1476-5381.2010.01046.x

Bridges D, Ahmad K, Rice AS. The synthetic cannabinoid WIN55,212-2 attenuates hyperalgesia and allodynia in a rat model of neuropathic pain. Br J Pharmacol. 2001;133(4):586-94. doi: https://doi.org/10.1038/sj.bjp.0704110

Pergolizzi JVJ, Lequang JA, Taylor RJ, Raffa RB, Colucci D. The role of cannabinoids in pain control: the good, the bad, and the ugly. Minerva Anestesiol. 2018;84(8):955-69. doi: https://doi.org/10.23736/S0375-9393.18.12287-5

van de Donk T, Niesters M, Kowal MA, Olofsen E, Dahan A, van Velzen M. An experimental randomized study on the analgesic effects of pharmaceutical-grade cannabis in chronic pain patients with fibromyalgia. Pain. 2019;160(4):860-9. doi: https://doi.org/10.1097/j.pain.0000000000001464

Weber J, Schley M, Casutt M, Gerber H, Schuepfer G, Rukwied R, et al. Tetrahydrocannabinol (Delta 9-THC) Treatment in chronic central neuropathic pain and fibromyalgia patients: Results of a multicenter survey. Anesthesiol Res Pract. 2009:827290. doi: https://doi.org/10.1155/2009/827290

Mücke M, Phillips T, Radbruch L, Petzke F, Häuser W. Cannabis-based medicines for chronic neuropathic pain in adults. Cochrane database Syst Rev. 2018;3(3):CD012182. doi: https://doi.org/10.1002/14651858.CD012182.pub2

Crestani F. Medical cannabis for the treatment of fibromyalgia. J Clin Rheumatol. 2018;24:281. doi: https://doi.org/10.1097/RHU.0000000000000823

Ledezma-Morales M, Cristina Rodríguez A, Amariles P. Mercado del Cannabis medicinal en Colombia: una oportunidad para el sector salud que requiere lineamientos estratégicos del gobierno nacional y la academia. Rev Médicas UIS. 2020;33(1):53-8. doi: https://doi.org/10.18273/revmed.v33n1-2020006

Fiz J, Durán M, Capellà D, Carbonell J, Farré M. Cannabis use in patients with fibromyalgia: effect on symptoms relief and health-related quality of life. PLoS One. 2011;6(4):e18440. doi: https://doi.org/10.1371/journal.pone.0018440

Habib G, Artul S. Medical cannabis for the treatment of fibromyalgia. J Clin Rheumatol Pract reports Rheum Musculoskelet Dis. 2018;24(5):255-8. doi: https://doi.org/10.1097/RHU.0000000000000702

Habib G, Levinger U. [Characteristics of medical cannabis usage among patients with fibromyalgia]. Harefuah. 2020;159(5):343-8.

How to Cite
1.
Mayorga Anaya HJ, Torres Ortiz MP, Flórez Valencia DH, Gomezese Ribero OF. Efficacy of cannabinoids in fibromyalgia: a literature review. Colomb. J. Anesthesiol. [Internet]. 2021Mar.26 [cited 2021Sep.27];49(4). Available from: https://www.revcolanest.com.co/index.php/rca/article/view/980

Downloads

Download data is not yet available.
Published
2021-03-26
How to Cite
1.
Mayorga Anaya HJ, Torres Ortiz MP, Flórez Valencia DH, Gomezese Ribero OF. Efficacy of cannabinoids in fibromyalgia: a literature review. Colomb. J. Anesthesiol. [Internet]. 2021Mar.26 [cited 2021Sep.27];49(4). Available from: https://www.revcolanest.com.co/index.php/rca/article/view/980
Section
Narrative review

More on this topic